U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Adenocarcinoma

MedGen UID:
1699198
•Concept ID:
C5204530
•
Neoplastic Process

Definition

An adenocarcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Adenocarcinoma

Professional guidelines

PubMed

Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Sarosi V, Losonczy G, Francovszky E, Tolnay E, Torok S, Galffy G, Hegedus B, Dome B, Ostoros G
Lung Cancer 2014 Oct;86(1):54-8. Epub 2014 Jul 27 doi: 10.1016/j.lungcan.2014.07.011. PMID: 25129367
Continuous-infusion vinblastine for treatment of refractory adenocarcinoma of the cervix.
Kavanagh JJ, Copeland L, Gershenson D, Roberts W
Cancer Treat Rep 1987 May;71(5):547-8. PMID: 3567982
Tamoxifen in the treatment of refractory adenocarcinoma of the cervix.
Kavanagh JJ, Wharton JT, Rutledge F
Cancer Treat Rep 1986 Jul;70(7):923-4. PMID: 3719587

Recent clinical studies

Etiology

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol.
Bissada NK, Kaczmarek AT
J Urol 1995 Jun;153(6):1944-5. PMID: 7752364
Radiotherapy for regionally localized hormone refractory prostate cancer.
Lankford SP, Pollack A, Zagars GK
Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):907-12. doi: 10.1016/0360-3016(95)02005-0. PMID: 7591901
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L
Cancer 1994 Mar 1;73(5):1453-5. doi: 10.1002/1097-0142(19940301)73:5<1453::aid-cncr2820730521>3.0.co;2-x. PMID: 8111713
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE
J Clin Oncol 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. PMID: 7523606
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA Jr
J Urol 1993 Aug;150(2 Pt 1):411-3. doi: 10.1016/s0022-5347(17)35496-4. PMID: 8326565

Diagnosis

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA, Herndon JE 2nd, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC; Cancer and Leukemia Group B
Cancer 2004 Nov 15;101(10):2202-8. doi: 10.1002/cncr.20655. PMID: 15484217
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ
J Clin Oncol 2003 Apr 1;21(7):1232-7. doi: 10.1200/JCO.2003.06.100. PMID: 12663709
Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells.
Donat SM, Powell CT, Israeli RS, Fair WR, Heston WD
J Natl Cancer Inst 1995 Jan 4;87(1):41-6. doi: 10.1093/jnci/87.1.41. PMID: 7666462
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
Babaian RJ, Hsu SD
Urology 1984 Mar;23(3):272-5. doi: 10.1016/s0090-4295(84)90046-3. PMID: 6546626

Therapy

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol.
Bissada NK, Kaczmarek AT
J Urol 1995 Jun;153(6):1944-5. PMID: 7752364
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L
Cancer 1994 Mar 1;73(5):1453-5. doi: 10.1002/1097-0142(19940301)73:5<1453::aid-cncr2820730521>3.0.co;2-x. PMID: 8111713
Continuous-infusion vinblastine for treatment of refractory adenocarcinoma of the cervix.
Kavanagh JJ, Copeland L, Gershenson D, Roberts W
Cancer Treat Rep 1987 May;71(5):547-8. PMID: 3567982
Tamoxifen in the treatment of refractory adenocarcinoma of the cervix.
Kavanagh JJ, Wharton JT, Rutledge F
Cancer Treat Rep 1986 Jul;70(7):923-4. PMID: 3719587
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
Babaian RJ, Hsu SD
Urology 1984 Mar;23(3):272-5. doi: 10.1016/s0090-4295(84)90046-3. PMID: 6546626

Prognosis

A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman BG, Esper PS, Flaherty LE
Am J Clin Oncol 1996 Oct;19(5):500-3. doi: 10.1097/00000421-199610000-00014. PMID: 8823479
Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol.
Bissada NK, Kaczmarek AT
J Urol 1995 Jun;153(6):1944-5. PMID: 7752364
Radiotherapy for regionally localized hormone refractory prostate cancer.
Lankford SP, Pollack A, Zagars GK
Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):907-12. doi: 10.1016/0360-3016(95)02005-0. PMID: 7591901
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE
J Clin Oncol 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. PMID: 7523606
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA Jr
J Urol 1993 Aug;150(2 Pt 1):411-3. doi: 10.1016/s0022-5347(17)35496-4. PMID: 8326565

Clinical prediction guides

Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer.
Kashiwabara K, Semba H, Fujii S, Tsumura S
Respir Investig 2016 Nov;54(6):468-472. Epub 2016 Aug 25 doi: 10.1016/j.resinv.2016.06.007. PMID: 27886859
Radiotherapy for regionally localized hormone refractory prostate cancer.
Lankford SP, Pollack A, Zagars GK
Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):907-12. doi: 10.1016/0360-3016(95)02005-0. PMID: 7591901
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L
Cancer 1994 Mar 1;73(5):1453-5. doi: 10.1002/1097-0142(19940301)73:5<1453::aid-cncr2820730521>3.0.co;2-x. PMID: 8111713
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE
J Clin Oncol 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. PMID: 7523606
Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung.
Ziegler LD, Palazzolo P, Cunningham J, Janus M, Itoh K, Hayakawa K, Hellstrom I, Hellstrom KE, Nicaise C, Dennin R
J Clin Oncol 1992 Sep;10(9):1470-8. doi: 10.1200/JCO.1992.10.9.1470. PMID: 1517790

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...